Business Context and Reporting Period
This Form 8-K Current Report was filed by Cartesian Therapeutics, Inc. on October 2, 2025. The filing discloses the appointment of a new executive officer, specifically the Chief Accounting Officer, effective October 27, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $385,000 annually.
- Target Bonus: 35% of annual base salary (prorated for 2025).
- Sign-on Bonus: $80,000.
- Equity Grant: Option to purchase 50,000 shares of common stock.
- Severance: Six months of base salary and COBRA coverage upon termination without cause or resignation for good reason.
Material Changes
The primary material change is the appointment of June Seymour as Chief Accounting Officer. Blaine Davis will continue to serve as the Company's Chief Financial Officer, principal financial officer, and principal accounting officer.
Outlook, Risks, and Unusual Items
The filing outlines standard restrictive covenants, including a 12-month non-compete and non-solicitation period following termination. The equity option vests over four years (25% after 12 months, then 25% annually). No specific business risks, contingencies, or unusual items regarding operations were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of employment (October 27, 2025) and the start of the vesting schedule for the 50,000 stock options.
- Verify the exercise price of the stock options, which is set to the closing price on the grant date.
- Review the definitions of "cause" and "good reason" in the employment agreement to understand severance triggers.
- Monitor future filings for any changes to the principal accounting officer designation, as Blaine Davis retains this title despite the new appointment.